148 related articles for article (PubMed ID: 17822667)
41. Interaction of the N-methyl-D-aspartic acid receptor NR2D subunit with the c-Abl tyrosine kinase.
Glover RT; Angiolieri M; Kelly S; Monaghan DT; Wang JY; Smithgall TE; Buller AL
J Biol Chem; 2000 Apr; 275(17):12725-9. PubMed ID: 10777567
[TBL] [Abstract][Full Text] [Related]
42. Two-state dynamics of the SH3-SH2 tandem of Abl kinase and the allosteric role of the N-cap.
Corbi-Verge C; Marinelli F; Zafra-Ruano A; Ruiz-Sanz J; Luque I; Faraldo-Gómez JD
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3372-80. PubMed ID: 23959873
[TBL] [Abstract][Full Text] [Related]
43. The tryptophan switch: changing ligand-binding specificity from type I to type II in SH3 domains.
Fernandez-Ballester G; Blanes-Mira C; Serrano L
J Mol Biol; 2004 Jan; 335(2):619-29. PubMed ID: 14672668
[TBL] [Abstract][Full Text] [Related]
44. The Tec family kinase Itk exists as a folded monomer in vivo.
Qi Q; August A
J Biol Chem; 2009 Oct; 284(43):29882-92. PubMed ID: 19717557
[TBL] [Abstract][Full Text] [Related]
45. The solution structure and intramolecular associations of the Tec kinase SRC homology 3 domain.
Pursglove SE; Mulhern TD; Mackay JP; Hinds MG; Booker GW
J Biol Chem; 2002 Jan; 277(1):755-62. PubMed ID: 11684687
[TBL] [Abstract][Full Text] [Related]
46. New insights into the activation of Escherichia coli tyrosine kinase revealed by molecular dynamics simulation and biochemical analysis.
Lu T; Tan H; Lee D; Chen G; Jia Z
Biochemistry; 2009 Aug; 48(33):7986-95. PubMed ID: 19634880
[TBL] [Abstract][Full Text] [Related]
47. Identification and kinetic analysis of the interaction between Nck-2 and DOCK180.
Tu Y; Kucik DF; Wu C
FEBS Lett; 2001 Mar; 491(3):193-9. PubMed ID: 11240126
[TBL] [Abstract][Full Text] [Related]
48. Quantitative relation between intermolecular and intramolecular binding of pro-rich peptides to SH3 domains.
Zhou HX
Biophys J; 2006 Nov; 91(9):3170-81. PubMed ID: 16891373
[TBL] [Abstract][Full Text] [Related]
49. Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus.
Ie Kim H; Lee ST
J Biochem; 2009 Jul; 146(1):133-9. PubMed ID: 19304789
[TBL] [Abstract][Full Text] [Related]
50. Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function.
Grover P; Shi H; Baumgartner M; Camacho CJ; Smithgall TE
PLoS One; 2015; 10(7):e0133590. PubMed ID: 26222440
[TBL] [Abstract][Full Text] [Related]
51. SH2-catalytic domain linker heterogeneity influences allosteric coupling across the SFK family.
Register AC; Leonard SE; Maly DJ
Biochemistry; 2014 Nov; 53(44):6910-23. PubMed ID: 25302671
[TBL] [Abstract][Full Text] [Related]
52. In Silico Screening of Multi-Domain Targeted Inhibitors for PTK6: A Strategy Integrating Drug Repurposing and Consensus Docking.
Zhou Y; Wong MW
Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256893
[TBL] [Abstract][Full Text] [Related]
53. A novel disulfide bond in the SH2 Domain of the C-terminal Src kinase controls catalytic activity.
Mills JE; Whitford PC; Shaffer J; Onuchic JN; Adams JA; Jennings PA
J Mol Biol; 2007 Feb; 365(5):1460-8. PubMed ID: 17137590
[TBL] [Abstract][Full Text] [Related]
54. Enhanced affinities and specificities of consolidated ligands for the Src homology (SH) 3 and SH2 domains of Abelson protein-tyrosine kinase.
Cowburn D; Zheng J; Xu Q; Barany G
J Biol Chem; 1995 Nov; 270(45):26738-41. PubMed ID: 7592905
[TBL] [Abstract][Full Text] [Related]
55. Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering.
Márquez JA; Smith CI; Petoukhov MV; Lo Surdo P; Mattsson PT; Knekt M; Westlund A; Scheffzek K; Saraste M; Svergun DI
EMBO J; 2003 Sep; 22(18):4616-24. PubMed ID: 12970174
[TBL] [Abstract][Full Text] [Related]
56. Both proline-rich sequences in the TH region of Bruton's tyrosine kinase stabilize intermolecular interactions with the SH3 domain.
Hansson H; Smith CI; Härd T
FEBS Lett; 2001 Nov; 508(1):11-5. PubMed ID: 11707259
[TBL] [Abstract][Full Text] [Related]
57. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition.
Qiu H; Miller WT
J Biol Chem; 2002 Sep; 277(37):34634-41. PubMed ID: 12121988
[TBL] [Abstract][Full Text] [Related]
58. PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1.
Kang SA; Lee ES; Yoon HY; Randazzo PA; Lee ST
J Biol Chem; 2010 Aug; 285(34):26013-21. PubMed ID: 20554524
[TBL] [Abstract][Full Text] [Related]
59. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics.
Verkhivker GM
Bioinformatics; 2007 Aug; 23(15):1919-26. PubMed ID: 17537753
[TBL] [Abstract][Full Text] [Related]
60. Co-crystal structures of PTK6: With Dasatinib at 2.24 Å, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 Å resolution.
Thakur MK; Birudukota S; Swaminathan S; Battula SK; Vadivelu S; Tyagi R; Gosu R
Biochem Biophys Res Commun; 2017 Jan; 482(4):1289-1295. PubMed ID: 27993680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
